Skip to main content
Download PDF

The association between hypoxia inducible factor 1 subunit alpha gene rs2057482 polymorphism and cancer risk: a meta-analysis

BMC Cancer volume 19, Article number: 1123 (2019) Cite this article

Abstract

Background

The rs2057482 polymorphism in the hypoxia inducible factor 1 subunit alpha (HIF1A) gene has been reported to be associated with a risk of several types of cancer, but this association has not yet been definitively confirmed. We performed this meta-analysis to determine whether rs2057482 is associated with overall cancer risk.

Methods

The PubMed, Embase, and Web of Science databases were searched for the potential studies about the association between the rs2057482 and cancer risk. The data of genotype frequencies in cases with cancer and controls were extracted from the selected studies. Odds ratios (ORs) and the corresponding 95% confidence intervals (CIs) were calculated to determine the strength of the associations.

Results

The meta-analysis showed an association between the rs2057482 polymorphism and overall cancer risk. However, a stratified analysis of ethnicity did not show any significant association between rs2057482 and cancer risk in the Asian population.

Conclusions

The rs2057482 polymorphism was associated with decreased overall cancer risk, based on the currently available studies. However, this conclusion needs verification by further well-designed epidemiology studies that examine different cancer types and more subjects.

Peer Review reports

Background

Hypoxia inducible factor 1 (HIF1) is a transcription factor that coordinates the response to hypoxia in cells and tissues [1]. HIF1 is a heterodimeric protein consisting of HIF1A and HIF1B subunits. The HIF1A subunit is induced by hypoxia and forms an active transcription inducer with HIF1B [2]. HIF1 activation promotes the expression of several hypoxia-adaptation genes, including those involved in the biological processes of angiogenesis, erythropoiesis, cell proliferation, and apoptosis [3, 4].

Hypoxia is a common issue in tumor tissues [5]. HIF1A regulates cellular adaptation to hypoxia and promotes tumor development [6,7,8]. HIF1A expression increases in various types of cancer, such as breast, prostate, and colon cancer [9], and a high expression of HIF1A in a tumor indicates poor patient prognosis [10]. The relapse-free survival time is significantly lower for the hepatocellular carcinoma patients with high expression of HIF1A than for patients with low expression [11].

The rs2057482 polymorphism is located in the 3′ untranslated region (3′-UTR) region of the HIF1A gene. The SNP has been widely explored for its relationship with cancer risk [12,13,14,15,16,17,18]. We performed this meta-analysis to provide a more accurate assessment and obtain a comprehensive understanding of the relationship between rs2057482 and cancer risk.

Methods

Search strategy

Three databases (PubMed, Embase, and Web of Science) were retrieved up to September 24, 2019, using the following keywords: “hypoxia inducible factor 1 subunit alpha or HIF1A,” “polymorphism or variant or mutation or SNP,” and “cancer or carcinoma or tumor.” We also checked the Ensembl web site for potential studies (http://asia.ensembl.org/Homo_sapiens/Variation).

Inclusion and exclusion criteria

The inclusion criteria were:

  1. 1.

    The study is about the relationship between rs2057482 and cancer risk.

  2. 2.

    The study is a case-control study or cohort study.

  3. 3.

    The study must contain sufficient genotype data for the meta-analysis.

  4. 4.

    The study is published in English.

We excluded reviews, meta-analyses, and abstracts.

Data extraction

The data from the selected studies were extracted by two authors separately. The extracted data were the following: first author; publication year; country or region where the study conducted; control source; genotype methods; and genotype frequencies.

Quality score

We evaluated the quality of these included studies by scoring each study based on the case and control source, number of subjects, and Hardy-Weinberg equilibrium (Additional file 1: Table S1) [19].

Statistical analysis

Statistical analyses were carried out using the Stata software (Version 12.0, Stata Corporation, College Station, TX). ORs and 95%Cls were calculated to evaluate the strength of the association between the rs2057482 polymorphism and cancer risk. P values < 0.05 were considered statistically significant. This meta-analysis used five genetic models: the allele (T vs. C), homozygote (TT vs. CC), heterozygote (CT vs. CC), dominant (TT + CT vs. CC), and recessive models (TT vs. CT + CC). We also conducted stratified analysis of ethnicity; however, only one study was about the Caucasian population, so we have only shown results for the Asian population. In addition, only one study was retrieved about each type of cancer, so we did not conduct a stratified analysis of cancer type. We measured the heterogeneity with the parameter I2 and the P-value with the Chi-squared test [20]. When I2 < 50% or P > 0.10, the fixed model was used [21]; otherwise, a random model was used [22]. Sensitivity analyses were performed by removing one study each time [23]. Publication bias was determined using the Egger and Begg tests [24, 25].

Results

Characteristics of the studies

The process used to select target articles is shown in Fig. 1. The database searches identified 949 studies after removing duplicate records. A further check of the titles and abstracts excluded 915 studies. We read the full text of the remaining 34 studies and ultimately selected 7 studies for the meta-analysis. The included studies were conducted between 2008 and 2018; five studies were about the Asian population, one was about the Caucasian population, and one was about a mixed population. The characteristics of these studies are shown in Table 1. The genotype frequencies are listed in Table 2.

Fig. 1
figure 1

The flow diagram of included/excluded studies

Full size image
Table 1 Characteristics of the studies included in the meta-analysis
Full size table
Table 2 HIF1A rs2057482 polymorphism genotype distribution and allele frequency in cases and controls
Full size table

Meta-analysis

In this meta-analysis, the overall analysis under the dominant genetic model showed a significant association between the rs2057482 polymorphism and a decreased risk of cancer (Table 3 and Fig. 2, TT + CT vs. CC: OR, 0.89, 95% CI, 0.81–0.98, P = 0.017). However, the stratified analysis of ethnicity did not indicate an association between rs2057482 and cancer risk in the Asian population in any of the genetic models (Table 3). We only synthesized the results if two or more studies were available, so the results for the Caucasian population were not shown.

Table 3 Meta-analysis of the association between rs2057482 polymorphism and cancer susceptibility
Full size table
Fig. 2
figure 2

Meta-analysis of the association between rs2057482 and risk of cancer a: allele model; b: homozygous model; c: heterozygous model; D: dominant model; E: recessive model. The squares and horizontal lines correspond to the study specific OR and 95% CI. The area of the squares reflects the weight. The diamond represents the summary OR and 95% CI. The random-effects model was used for the heterozygous genetic model, and fixed-effects models were used for other genetic models.

Full size image

Sensitivity analysis

Sensitivity analyses were performed using the metainf command. Exclusion of the Qin2011 study led to a different result in the allele model, and exclusion of the Wang2016 study led to a different result in the dominant model (Fig. 3 and Additional file 1: Table S2). We also preformed sensitivity analyses in Asian populations. Exclusion of the Qin2011 study led to a different result in the allele model (Additional file 1: Table S3). These results suggest that our results were not stable in these models.

Fig. 3
figure 3

Sensitivity analyses between rs2057482 polymorphism and risk of cancer a: allele model; b: homozygous model; c: heterozygous model; d: dominant model; e: recessive model. The random-effects model was used for the heterozygous genetic model, and fixed-effects models were used for other genetic models.

Full size image

Publication bias

Egger and Begg tests carried out to detect potential publication bias revealed no publication bias in this meta-analysis (Table 4).

Table 4 Publication bias analysis
Full size table

Discussion

HIF1A plays a central role in tumor adaptation to hypoxia [26, 27]. HIF1A mediates the hypoxic adaptation of tumor cells and tissues in multiple ways [28]. For example, angiogenesis is an important aspect of cancer progression, and HIF1A contributes to tumor angiogenesis by upregulating vascular endothelial growth factor (VEGF) and other proangiogenic factors [29, 30]. HIF1A also increases the expression of multiple enzymes involved in glycolysis, which further aids tumor cell growth and proliferation [31,32,33,34]. In addition, HIF1A promotes autophagy by altering the expression of BCL2/adenovirus E1B 19 kDa protein-interacting protein 3 (BNIP3), which is part of a stress adaptation mechanism that promotes tumor cell survival and avoids cell death [35, 36]. Many studies have reported associations between HIF1A polymorphisms and the risks of various types of cancer, including bladder, oral, and colorectal cancers, head and neck squamous cell carcinoma, and renal cell carcinoma [37,38,39,40].

The HIF1A gene has many SNPs, but we focused on rs2057482 for the following reasons: First, the relationship between rs2057482 and cancer risk has been reported in previous epidemiology studies [12,13,14,15,16,17,18]. Second, in the 1000 Genomes Project Phase 3, minor allele frequencies of rs2057482 are greater than 10% in most populations (Additional file 1: Table S4). Third, the selected SNP may have important biological functions, according to previous reports.

The rs2057482 polymorphism is located in the 3’UTR of HIF1A. Many researchers have hypothesized that this polymorphism may be located near the microRNA binding site and that it affects the expression of HIF1A by binding HIF1A to the microRNA [13, 15,16,17,18]. Wang et al. reported that rs2057482 may affect the expression of HIF1A by microRNA 199a [15]. Gregory et al., based on silico analyses with the miRNA-SNP analytic tool TargetScan 5.2, suggested that the T allele of HIF1A rs2057482 created new microRNA binding sites for microRNA 196a-2 [17].

The rs2057482 polymorphism has been reported to associate with the occurrence and prognosis of several kinds of cancer [41,42,43,44]. For example, this polymorphism was found to decrease the risk of non-Hodgkin’s lymphoma associated with central nervous system acquired immune deficiency syndrome [17]. An association has also been reported between rs2057482 polymorphism and prognosis of early-stage lung cancer patients after surgery [45]. In addition, the recurrence rate of hepatocellular carcinoma is lower in CT + TT carrier patients than in CC carrier patients [11].

Our meta-analysis revealed that rs2057482 decreased the overall cancer risk in the dominant genetic model. We hypothesize that the carrier of the T allele (CT + TT) creates a new microRNA binding site. Binding leads to decreased expression of HIF1A, thereby reducing the risk of cancer. However, this conclusion is made based on only seven types of tumor (breast, lung, prostate cancer, pancreatic ductal adenocarcinoma, renal cell carcinoma, non-Hodgkin’s lymphoma, and multiple myeloma); therefore, we suggest that the relationship between rs2057482 and more types of cancer should be investigated in further studies.

The current meta-analysis has the following limitations that should be recognized. First, the number of studies contained in the meta-analysis is limited, and the majority of the study populations were Asians. The genomic effect of this SNP could be ethnicity specific, so this prevalence of Asian subjects may have biased the results for overall cancer risk. The present study results therefore only provide meaningful information for Asian populations, and we recommend additional research on the risk of cancer and rs2057482 in Caucasian and other populations in the future. Second, only one study was included for each cancer type, so we did not conduct a stratified analysis based on cancer type. Each type of cancer may have a different underlying genomic mechanism, so more studies on rs2057482 and cancer risk are needed for each type of cancer. Finally, the mechanism by which this SNP affects tumor risk is still unclear and needs further exploration.

Conclusions

Our meta-analysis suggests that the rs205782 polymorphism of the HIF1A gene significantly decreases the overall cancer risk, based on the synthesis results of the included studies. This conclusion should be further verified by additional studies that include more subjects and cancer types.

Availability of data and materials

All data generated or analysed during this study are included in this published article and its supplementary information files.

Abbreviations

3′-UTR:

three prime untranslated region

BNIP3:

BCL2/adenovirus E1B 19 kDa protein-interacting protein 3

CI:

confidence interval

HB:

hospital-based

HIF1:

hypoxia inducible factor 1

HWE:

Hardy-Weinberg equilibrium

MAF:

minor allele frequency

MM:

multiple myeloma

NHL:

non-Hodgkin lymphoma

OR:

odds ratio

PB:

population-based

PDAC:

pancreatic ductal adenocarcinoma

RCC:

renal cell carcinoma

SNP:

single nucleotide polymorphism

VEGF:

vascular endothelial growth factor

References

  1. 1.

    Wang GL, Semenza GL. Purification and characterization of hypoxia-inducible factor 1. J Biol Chem. 1995;270(3):1230–7. https://doi.org/10.1074/jbc.270.3.1230.

    CAS  Article  PubMed  Google Scholar 

  2. 2.

    Baldewijns MM, van Vlodrop IJ, Vermeulen PB, Soetekouw PM, van Engeland M, de Bruine AP. VHL and HIF signalling in renal cell carcinogenesis. J Pathol. 2010;221(2):125–38. https://doi.org/10.1002/path.2689.

    CAS  Article  PubMed  Google Scholar 

  3. 3.

    Semenza GL. Targeting HIF-1 for cancer therapy. Nat Rev Cancer. 2003;3(10):721–32. https://doi.org/10.1038/nrc1187.

    CAS  Article  PubMed  Google Scholar 

  4. 4.

    Tanimoto K, Yoshiga K, Eguchi H, Kaneyasu M, Ukon K, Kumazaki T, Oue N, Yasui W, Imai K, Nakachi K, et al. Hypoxia-inducible factor-1alpha polymorphisms associated with enhanced transactivation capacity, implying clinical significance. Carcinogenesis. 2003;24(11):1779–83. https://doi.org/10.1093/carcin/bgg132.

    CAS  Article  PubMed  Google Scholar 

  5. 5.

    Semenza GL. The hypoxic tumor microenvironment: a driving force for breast cancer progression. Biochim Biophys Acta. 2016;1863(3):382–91. https://doi.org/10.1016/j.bbamcr.2015.05.036.

    CAS  Article  PubMed  Google Scholar 

  6. 6.

    Leek RD, Talks KL, Pezzella F, Turley H, Campo L, Brown NS, Bicknell R, Taylor M, Gatter KC, Harris AL. Relation of hypoxia-inducible factor-2 alpha (HIF-2 alpha) expression in tumor-infiltrative macrophages to tumor angiogenesis and the oxidative thymidine phosphorylase pathway in human breast cancer. Cancer Res. 2002;62(5):1326–9.

    CAS  PubMed  Google Scholar 

  7. 7.

    Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura K, Hosokawa M, Asaka M. Constitutive expression of hypoxia-inducible factor-1alpha renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res. 2001;61(17):6548–54.

    CAS  PubMed  Google Scholar 

  8. 8.

    Hayashi Y, Yokota A, Harada H, Huang G. Hypoxia/pseudohypoxia-mediated activation of hypoxia-inducible factor-1alpha in cancer. Cancer Sci. 2019;110(5):1510–7. https://doi.org/10.1111/cas.13990.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  9. 9.

    Zhong H, De Marzo AM, Laughner E, Lim M, Hilton DA, Zagzag D, Buechler P, Isaacs WB, Semenza GL, Simons JW. Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. Cancer Res. 1999;59(22):5830–5.

    CAS  PubMed  Google Scholar 

  10. 10.

    Baba Y, Nosho K, Shima K, Irahara N, Chan AT, Meyerhardt JA, Chung DC, Giovannucci EL, Fuchs CS, Ogino S. HIF1A overexpression is associated with poor prognosis in a cohort of 731 colorectal cancers. Am J Pathol. 2010;176(5):2292–301. https://doi.org/10.2353/ajpath.2010.090972.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  11. 11.

    Guo X, Li D, Chen Y, An J, Wang K, Xu Z, Chen Z, Xing J. SNP rs2057482 in HIF1A gene predicts clinical outcome of aggressive hepatocellular carcinoma patients after surgery. Sci Rep. 2015;5:11846. https://doi.org/10.1038/srep11846.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  12. 12.

    Lee JY, Choi JY, Lee KM, Park SK, Han SH, Noh DY, Ahn SH, Kim DH, Hong YC, Ha E et al: Rare variant of hypoxia-inducible factor-1alpha (HIF-1A) and breast cancer risk in Korean women. Clinica chimica acta; international journal of clinical chemistry 2008, 389(1–2):167–170. https://doi.org/10.1016/j.cca.2007.12.005.

  13. 13.

    Qin C, Cao Q, Ju X, Wang M, Meng X, Zhu J, Yan F, Li P, Ding Q, Chen J, et al. The polymorphisms in the VHL and HIF1A genes are associated with the prognosis but not the development of renal cell carcinoma. Ann Oncol. 2012;23(4):981–9. https://doi.org/10.1093/annonc/mdr325.

    CAS  Article  PubMed  Google Scholar 

  14. 14.

    Li P, Cao Q, Shao PF, Cai HZ, Zhou H, Chen JW, Qin C, Zhang ZD, Ju XB, Yin CJ. Genetic polymorphisms in HIF1A are associated with prostate cancer risk in a Chinese population. Asian journal of andrology. 2012;14(6):864–9. https://doi.org/10.1038/aja.2012.101.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  15. 15.

    Wang X, Ren H, Zhao T, Ma W, Dong J, Zhang S, Xin W, Yang S, Jia L, Hao J. Single nucleotide polymorphism in the microRNA-199a binding site of HIF1A gene is associated with pancreatic ductal adenocarcinoma risk and worse clinical outcomes. Oncotarget. 2016;7(12):13717–29. https://doi.org/10.18632/oncotarget.7263.

    Article  PubMed  PubMed Central  Google Scholar 

  16. 16.

    Yamamoto Y, Kiyohara C, Ogata-Suetsugu S, Hamada N, Nakanishi Y. Association between genetic polymorphisms involved in the hypoxia-inducible factor pathway and lung cancer risk: a case-control study in Japan. Asia-Pacific journal of clinical oncology. 2017;13(3):234–42. https://doi.org/10.1111/ajco.12640.

    Article  PubMed  Google Scholar 

  17. 17.

    Peckham-Gregory EC, Thapa DR, Martinson J, Duggal P, Penugonda S, Bream JH, Chang PY, Dandekar S, Chang SC, Detels R, et al. MicroRNA-related polymorphisms and non-Hodgkin lymphoma susceptibility in the multicenter AIDS cohort study. Cancer Epidemiol. 2016;45:47–57. https://doi.org/10.1016/j.canep.2016.09.007.

    Article  PubMed  PubMed Central  Google Scholar 

  18. 18.

    Almasi M, Besse L, Brozova L, Jarkovsky J, Bezdekova R, Pour L, Minarik J, Kessler P, Pavlicek P, Roziakova L, et al. Selected genetic polymorphisms associated with hypoxia and multidrug resistance in monoclonal Gammopathies patients. Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti. 2018;31(3):213–29. https://doi.org/10.14735/amko2018213.

    Article  Google Scholar 

  19. 19.

    Tian X, Dai S, Sun J, Jiang S, Jiang Y. Association between TP53 Arg72Pro polymorphism and leukemia risk: a meta-analysis of 14 case-control studies. Sci Rep. 2016;6. https://doi.org/10.1038/srep24097.

  20. 20.

    Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. Stat Med. 2002;21(11):1539–58. https://doi.org/10.1002/sim.1186.

    Article  PubMed  PubMed Central  Google Scholar 

  21. 21.

    Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959;22(4):719–48.

    CAS  PubMed  Google Scholar 

  22. 22.

    DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986;7(3):177–88.

    CAS  Article  Google Scholar 

  23. 23.

    Steichen T. METANINF: Stata module to evaluate influence of a single study in meta-analysis estimation. Stat Softw Components. 2001.

  24. 24.

    Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994;50(4):1088–101.

    CAS  Article  Google Scholar 

  25. 25.

    Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. Bmj. 1997;315(7109):629–34.

    CAS  Article  Google Scholar 

  26. 26.

    Nagaraju GP, Bramhachari PV, Raghu G, El-Rayes BF. Hypoxia inducible factor-1alpha: its role in colorectal carcinogenesis and metastasis. Cancer Lett. 2015;366(1):11–8. https://doi.org/10.1016/j.canlet.2015.06.005.

    CAS  Article  PubMed  Google Scholar 

  27. 27.

    Zhang H, Lu H, Xiang L, Bullen JW, Zhang C, Samanta D, Gilkes DM, He J, Semenza GL. HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells. Proc Natl Acad Sci U S A. 2015;112(45):E6215–23. https://doi.org/10.1073/pnas.1520032112.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  28. 28.

    Ajdukovic J. HIF-1--a big chapter in the cancer tale. Exp Oncol. 2016;38(1):9–12.

    CAS  Article  Google Scholar 

  29. 29.

    Forsythe JA, Jiang BH, Iyer NV, Agani F, Leung SW, Koos RD, Semenza GL. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol. 1996;16(9):4604–13. https://doi.org/10.1128/mcb.16.9.4604.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  30. 30.

    Kelly BD, Hackett SF, Hirota K, Oshima Y, Cai Z, Berg-Dixon S, Rowan A, Yan Z, Campochiaro PA, Semenza GL. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ Res. 2003;93(11):1074–81. https://doi.org/10.1161/01.res.0000102937.50486.1b.

    CAS  Article  PubMed  Google Scholar 

  31. 31.

    Unwith S, Zhao H, Hennah L, Ma D. The potential role of HIF on tumour progression and dissemination. Int J Cancer. 2015;136(11):2491–503. https://doi.org/10.1002/ijc.28889.

    CAS  Article  PubMed  Google Scholar 

  32. 32.

    Yuneva M: Finding an "Achilles' heel" of cancer: the role of glucose and glutamine metabolism in the survival of transformed cells. Cell cycle (Georgetown, Tex) 2008, 7(14):2083–2089. https://doi.org/10.4161/cc.7.14.6256.

  33. 33.

    Gess B, Hofbauer KH, Deutzmann R, Kurtz A. Hypoxia up-regulates triosephosphate isomerase expression via a HIF-dependent pathway. Pflugers Archiv : European journal of physiology. 2004;448(2):175–80. https://doi.org/10.1007/s00424-004-1241-1.

    CAS  Article  PubMed  Google Scholar 

  34. 34.

    Lu S, Gu X, Hoestje S, Epner DE: Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter. Biochim Biophys Acta 2002, 1574(2):152–156. https://doi.org/10.1016/s0167-4781(01)00359-1.

  35. 35.

    Soni S, Padwad YS: HIF-1 in cancer therapy: two decade long story of a transcription factor. Acta oncologica (Stockholm, Sweden) 2017, 56(4):503–515. https://doi.org/10.1080/0284186x.2017.1301680.

  36. 36.

    Walls KC, Ghosh AP, Ballestas ME, Klocke BJ. Roth KA: bcl-2/adenovirus E1B 19-kd interacting protein 3 (BNIP3) regulates hypoxia-induced neural precursor cell death. J Neuropathol Exp Neurol. 2009;68(12):1326–38. https://doi.org/10.1097/NEN.0b013e3181c3b9be.

    CAS  Article  PubMed  PubMed Central  Google Scholar 

  37. 37.

    Fransen K, Fenech M, Fredrikson M, Dabrosin C, Soderkvist P. Association between ulcerative growth and hypoxia inducible factor-1alpha polymorphisms in colorectal cancer patients. Mol Carcinog. 2006;45(11):833–40. https://doi.org/10.1002/mc.20209.

    CAS  Article  PubMed  Google Scholar 

  38. 38.

    Ollerenshaw M, Page T, Hammonds J, Demaine A. Polymorphisms in the hypoxia inducible factor-1alpha gene (HIF1A) are associated with the renal cell carcinoma phenotype. Cancer Genet Cytogenet. 2004;153(2):122–6. https://doi.org/10.1016/j.cancergencyto.2004.01.014.

    CAS  Article  PubMed  Google Scholar 

  39. 39.

    Li XD, Zi H, Fang C, Zeng XT. Association between HIF1A rs11549465 polymorphism and risk of prostate cancer: a meta-analysis. Oncotarget. 2017;8(27):44910–6. https://doi.org/10.18632/oncotarget.16489.

    Article  PubMed  PubMed Central  Google Scholar 

  40. 40.

    Kang MJ, Jung SA, Jung JM, Kim SE, Jung HK, Kim TH, Shim KN, Yi SY, Yoo K, Moon IH. Associations between single nucleotide polymorphisms of MMP2, VEGF, and HIF1A genes and the risk of developing colorectal cancer. Anticancer Res. 2011;31(2):575–84.

    CAS  PubMed  Google Scholar 

  41. 41.

    Munoz-Guerra MF, Fernandez-Contreras ME, Moreno AL, Martin ID, Herraez B, Gamallo C. Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. Ann Surg Oncol. 2009;16(8):2351–8. https://doi.org/10.1245/s10434-009-0503-8.

    Article  PubMed  Google Scholar 

  42. 42.

    Nadaoka J, Horikawa Y, Saito M, Kumazawa T, Inoue T, Narita S, Yuasa T, Satoh S, Nishiyama H, Ogawa O, et al. Prognostic significance of HIF-1 alpha polymorphisms in transitional cell carcinoma of the bladder. Int J Cancer. 2008;122(6):1297–302. https://doi.org/10.1002/ijc.23256.

    CAS  Article  PubMed  Google Scholar 

  43. 43.

    Cai FF, Xu C, Pan X, Cai L, Lin XY, Chen S, Biskup E. Prognostic value of plasma levels of HIF-1a and PGC-1a in breast cancer. Oncotarget. 2016;7(47):77793–806. https://doi.org/10.18632/oncotarget.12796.

    Article  PubMed  PubMed Central  Google Scholar 

  44. 44.

    Hoffmann AC, Mori R, Vallbohmer D, Brabender J, Klein E, Drebber U, Baldus SE, Cooc J, Azuma M, Metzger R et al: High expression of HIF1a is a predictor of clinical outcome in patients with pancreatic ductal adenocarcinomas and correlated to PDGFA, VEGF, and bFGF. Neoplasia (New York, NY) 2008, 10(7):674–679. https://doi.org/10.1593/neo.08292.

  45. 45.

    Liu B, Liu Q, Song Y, Li X, Wang Y, Wan S, Zhang Z, Su H: Polymorphisms of HIF1A gene are associated with prognosis of early stage non-small-cell lung cancer patients after surgery. Medical oncology (Northwood, London, England) 2014, 31(4):877. https://doi.org/10.1007/s12032-014-0877-8.

Download references

Acknowledgements

Not applicable.

Funding

Publication costs are funded by funding from the National Natural Science Foundation of China (Grant No. 81601826).

Author information

Author notes

  1. Li-Fang Wu and Gui-Ping Xu contributed equally to this work.

Affiliations

  1. Department of Laboratory Medicine, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, 400010, China

    Li-Fang Wu, Qing Zhao, Li-Jing Zhou, Ding Wang & Wei-Xian Chen

  2. Transfusion Department, The Second Affiliated Hospital of Chongqing Medical University, Chongqing, China

    Gui-Ping Xu

Authors
  1. Li-Fang Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Gui-Ping Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Qing Zhao
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Li-Jing Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Ding Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Wei-Xian Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

Conceived and designed the meta-analysis:WXC,GPX, LFW. Searched the databases: LFW, QZ, LJZ. Analyzed the data: GPX,DW. Revised the manuscript: WXC, GPX. Wrote the paper: LFW. All authors have read and approved the final submitted manuscript.

Corresponding author

Correspondence to Wei-Xian Chen.

Ethics declarations

Ethics approval and consent to participate

Not applicable.

Consent for publication

Not applicable.

Competing interests

The authors declare they have no conflicts of interest.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Additional file 1: Table S1.

Quality score assessment. Table S2. Sensitivity analyses for rs2057482 polymorphism and cancer susceptibility. Table S3. Sensitivity analyses for rs2057482 polymorphism and cancer susceptibility in Asian population. Table S4. MAFs of rs2057482 polymorphism in the populations from the 1000 Genomes Project Phase 3.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Wu, LF., Xu, GP., Zhao, Q. et al. The association between hypoxia inducible factor 1 subunit alpha gene rs2057482 polymorphism and cancer risk: a meta-analysis. BMC Cancer 19, 1123 (2019). https://doi.org/10.1186/s12885-019-6329-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: https://doi.org/10.1186/s12885-019-6329-2

Keywords

  • HIF1A
  • Cancer
  • Meta-analysis
  • Polymorphism
  • rs2057482

BMC Cancer

ISSN: 1471-2407

Contact us